← Eichor
Condition: Muscle Invasive Bladder Urothelial Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Muscle Invasive Bladder Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
Phase N/A · 1 location(s) · OHSU Knight Cancer Institute · NCT07726602Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Pa
Phase 2 · 16 location(s) · Theralase® Technologies Inc. · NCT03945162Chemoablation for Low-Grade Bladder Cancer
Phase 2 · 1 location(s) · Ekaterina Laukhtina · NCT07019220Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invas
Phase 3 · 11 location(s) · Astellas Pharma Global Development, Inc. · NCT07566156Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
NA · 2 location(s) · Johns Hopkins University · NCT07225205Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bl
Phase N/A · 23 location(s) · Convergent Genomics, Inc. · NCT07673016Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06170177Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Phase 2 · 1 location(s) · Leslie Ballas · NCT06417190Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
Phase 2 · 1 location(s) · Yung NA · NCT06257017Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Phase 2 · 5 location(s) · Matthew Galsky · NCT06809140Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours
Phase 4 · 1 location(s) · University of Roma La Sapienza · NCT05962541A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Phase 1 · 17 location(s) · Aura Biosciences · NCT05483868Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Phase 2 · 1 location(s) · University of California, Irvine · NCT06682728Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
Phase N/A · 2 location(s) · Fox Chase Cancer Center · NCT06396533Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
NA · 2 location(s) · Thomas Jefferson University · NCT07234968A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Phase 2 · 4 location(s) · John Sfakianos · NCT06503614Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Amon
NA · 1 location(s) · University of Washington · NCT07302230Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · 499 location(s) · National Cancer Institute (NCI) · NCT05987241DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Phase 3 · 1 location(s) · Fudan University · NCT07207824EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
Phase 2 · 1 location(s) · Peking University Third Hospital · NCT07647289Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Phase 1 · 1 location(s) · Shilpa Gupta, MD · NCT05833867Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06167356Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva
Phase 2 · 160 location(s) · National Cancer Institute (NCI) · NCT07061964Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
Phase 3 · 1 location(s) · University of Rome Tor Vergata · NCT07067749An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With
Phase 3 · 160 location(s) · AstraZeneca · NCT07720284Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive B
Phase 3 · 6 location(s) · Verity Pharmaceuticals Inc. · NCT05037279Pan-tumor MRD Study
Phase N/A · 2 location(s) · Paradigm Health · NCT06605404A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Mi
Phase N/A · 1 location(s) · Peking University First Hospital · NCT06991868Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Gro
Phase 2 · 23 location(s) · Spanish Oncology Genito-Urinary Group · NCT06511648Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Partici
Phase 3 · 6 location(s) · Protara Therapeutics · NCT07480356
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.